Ambu A/ S stock (DK0060946788): UBS cuts price target amid share buyback progress

Ambu A/S, the Danish medtech company, reported transactions under its ongoing share buyback program, with DKK 280,334,895 remaining as of early May 2026, according to Marketscreener as of May 2026. Separately, UBS cut its price target for the stock to DKK 96 from 138 while reiterating a Buy rating, per Marketscreener as of 2026. The buyback, launched May 6, 2026, targets up to DKK 300m in repurchases through September 30, 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Ambu A/S: core business model

Ambu A/S develops, produces, and markets single-use medical devices for hospitals and emergency services worldwide. The company pioneered sterile, single-use flexible endoscopes, focusing on endoscopy procedures in pulmonology, urology, and ENT. Its portfolio includes bronchoscopes, cystoscopes, and airway management solutions like face masks for resuscitators.

Headquartered in Denmark, Ambu emphasizes innovation in disposable devices to reduce infection risks compared to reusable alternatives. This model supports growth in medtech markets demanding hygiene standards, with products sold globally including in the US.

Main revenue and product drivers for Ambu A/S

Key revenue comes from single-use endoscopy devices, which dominate sales amid rising demand for infection-preventive tech. The flexible endoscope market is projected to reach USD 22.7 billion by 2035 at 6% CAGR, per a GlobeNewswire report as of May 11, 2026, where Ambu is listed as a leader.

Airway management and anesthesia products, such as face masks, also drive income. US investors note Ambu's exposure via ambuusa.com, tapping North American hospital demand.

Industry trends and competitive position

The shift to single-use devices accelerates post-COVID, favoring Ambu's expertise. Competitors include Olympus and Boston Scientific, but Ambu's focus on disposables positions it for US market growth in outpatient procedures.

Why Ambu A/S matters for US investors

Ambu's products serve US healthcare, a key growth driver amid aging populations and endoscopy procedure rises. Listed on Nasdaq Copenhagen, it offers US retail investors access to European medtech via ADRs or direct trading, with relevance to domestic trends in infection control.

Conclusion

Ambu A/S progresses its share buyback while navigating analyst adjustments like UBS's lowered target. The company's single-use medtech focus aligns with global hygiene trends, offering exposure for US investors to endoscopy growth. Ongoing program execution and market positioning remain key watches.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.